Teva Pharmaceutical Industries Limited (NYSE: TEVA) on May 19, 2023, started off the session at the price of $8.295, plunging -4.24% from the previous trading day. During the day, the shares moved up to $8.36 and dropped to $7.895 before settling in for the closing price of $8.26. Within the past 52 weeks, TEVA’s price has moved between $6.78 and $11.44.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -7.80% annually for the last half of the decade. The company achieved an average annual earnings per share of -662.70%. With a float of $1.10 billion, this company’s outstanding shares have now reached $1.11 billion.
In an organization with 34004 employees, it is important to assess its efficiency. In terms of profitability, gross margin is +46.68, operating margin of +17.96, and the pretax margin is -20.55.
Teva Pharmaceutical Industries Limited (TEVA) Insider Updates
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The most recent insider transaction that took place on Mar 07, was worth 547,440. In this transaction EVP, North America Commercial of this company sold 58,066 shares at a rate of $9.43, taking the stock ownership to the 165,381 shares. Before that another transaction happened on Mar 07, when Company’s Exec. VP, European Commercial sold 54,007 for $9.43, making the entire transaction worth $509,173. This insider now owns 69,770 shares in total.
Teva Pharmaceutical Industries Limited (TEVA) Performance Highlights and Predictions
As on 3/30/2023, Multinational firm has announced its last quarter scores, in which it reported $0.4 earnings per share (EPS) for the period falling under the consensus outlook (set at $0.56) by -$0.16. This company achieved a net margin of -15.78 while generating a return on equity of -26.42. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -662.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.60% during the next five years compared to 34.30% growth over the previous five years of trading.
Teva Pharmaceutical Industries Limited (NYSE: TEVA) Trading Performance Indicators
Teva Pharmaceutical Industries Limited (TEVA) is currently performing well based on its current performance indicators. A quick ratio of 0.70 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.64. Likewise, its price to free cash flow for the trailing twelve months is 9.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.44, a number that is poised to hit 0.53 in the next quarter and is forecasted to reach 2.46 in one year’s time.
Technical Analysis of Teva Pharmaceutical Industries Limited (TEVA)
Let’s dig in a bit further. During the last 5-days, its volume was 29.97 million. That was better than the volume of 10.64 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 15.00%. Additionally, its Average True Range was 0.31.
During the past 100 days, Teva Pharmaceutical Industries Limited’s (TEVA) raw stochastic average was set at 0.42%, which indicates a significant decrease from 1.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.11% in the past 14 days, which was higher than the 40.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.67, while its 200-day Moving Average is $9.21. However, in the short run, Teva Pharmaceutical Industries Limited’s stock first resistance to watch stands at $8.22. Second resistance stands at $8.52. The third major resistance level sits at $8.68. If the price goes on to break the first support level at $7.75, it is likely to go to the next support level at $7.59. Assuming the price breaks the second support level, the third support level stands at $7.29.
Teva Pharmaceutical Industries Limited (NYSE: TEVA) Key Stats
Market capitalization of the company is 9.60 billion based on 1,110,900K outstanding shares. Right now, sales total 14,925 M and income totals -2,353 M. The company made 3,661 M in profit during its latest quarter, and -205,000 K in sales during its previous quarter.
